• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human psychopharmacology: clinical and experimental >The effect of escitalopram on sleep problems in depressed patients.
【24h】

The effect of escitalopram on sleep problems in depressed patients.

机译：酞普兰在睡眠问题的影响抑郁症患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The results from three 8-week escitalopram studies in major depressive disorder are presented with respect to efficacy and the effect on sleep quality, both in the full population and the subpopulation of patients with sleep problems at baseline.Analysis of pooled data from these randomized, double-blind, placebo-controlled, studies in which citalopram was the active reference, showed a significant improvement for escitalopram-treated patients (n = 52.0) in the Montgomery-Asberg depression rating scale (MADRS) item 4 ('reduced sleep') scores at weeks 6 and 8 compared with placebo (n=398; p or = 4; n = 254) at baseline showed a statistically significant improvement in mean MADRS item 4 scores at weeks 4, 6 and 8 compared with patients treated with placebo (n = 191; p < 0.05) or citalopram (n = 193; p < 0.01). These patients also showed a statistically significant (p < 0.05) and clinically relevant improvement in MADRS total score after escitalopram treatment compared with citalopram at weeks 1, 4, 6 and 8 (observed cases) and endpoint (-2.45; last observation carried forward [LOCF]). Statistical significance in favour of escitalopram versus placebo treatment was found at all visits, including endpoint (-4.2; LOCF).Thus, these post-hoc analyses suggest that escitalopram has a significant beneficial effect compared with placebo or citalopram in reducing sleep disturbance in patients suffering from major depressive disorder. The effect of escitalopram in improving 'reduced sleep' scores was clearly seen in patients with more severe sleep disturbance at baseline. A further prospective study is needed to establish this useful clinical effect in insomniac depressives.
机译：研究结果从三个8周酞提出了在重度抑郁症对疗效和影响睡眠在整个人口和质量分组人口患者的睡眠问题基线。随机、双盲、安慰剂对照,西酞普兰是积极的研究参考,显示出了极大的提高escitalopram-treated病人(n = 52.0)内在蒙哥马利抑郁量表(MADRS)第四项(“减少睡眠”)分数在周6和8与安慰剂比较(n = 398;周4、6和8 (n = 403;西酞普兰。与睡眠问题(MADRS第四项得分> = 4;在基线显示统计n = 254)显著的改善意味着MADRS第四项分数在周4、6和8与病人治疗与安慰剂组(n = 191;西酞普兰(n = 193;也显示出统计学意义(p <0.05)和临床相关的改善MADRS总分后酞普兰治疗相比之下,西酞普兰在周1,4,6,8(观察到的情况下)和端点(-2.45;观察结转[LOCF])。支持酞与意义安慰剂治疗被发现在所有访问,包括端点(-4.2;因果分析表明,酞重要而有益的影响在减少睡眠安慰剂或西酞普兰在患者主要干扰抑郁障碍。在提高成绩显然是减少睡眠在患者更严重的睡眠在基线干扰。临床研究需要建立这个有用失眠症患者抑郁症患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号